These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36835608)

  • 21. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
    Wigal SB; Childress A; Berry SA; Belden H; Walters F; Chappell P; Sherman N; Orazem J; Palumbo D
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):690-699. PubMed ID: 28557548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Methylphenidate on Sleep Functioning in Children with Attention-Deficit/Hyperactivity Disorder.
    Becker SP; Froehlich TE; Epstein JN
    J Dev Behav Pediatr; 2016 Jun; 37(5):395-404. PubMed ID: 27011002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.
    Riggs PD; Winhusen T; Davies RD; Leimberger JD; Mikulich-Gilbertson S; Klein C; Macdonald M; Lohman M; Bailey GL; Haynes L; Jaffee WB; Haminton N; Hodgkins C; Whitmore E; Trello-Rishel K; Tamm L; Acosta MC; Royer-Malvestuto C; Subramaniam G; Fishman M; Holmes BW; Kaye ME; Vargo MA; Woody GE; Nunes EV; Liu D
    J Am Acad Child Adolesc Psychiatry; 2011 Sep; 50(9):903-14. PubMed ID: 21871372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Testicular Function After Long-Term Methylphenidate Treatment in Boys with Attention-Deficit/Hyperactivity Disorder.
    Wang LJ; Lee SY; Chou WJ; Lee MJ; Tsai CS; Lee TL; Yang CJ; Yang KC; Chen CK; Shyu YC
    J Child Adolesc Psychopharmacol; 2019 Aug; 29(6):433-438. PubMed ID: 30575416
    [No Abstract]   [Full Text] [Related]  

  • 25. Attention-deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study.
    Germinario EA; Arcieri R; Bonati M; Zuddas A; Masi G; Vella S; Chiarotti F; Panei P;
    J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):440-7. PubMed ID: 24024538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of methylphenidate on leptin and appetite in children with attention-deficit hyperactivity disorder: an open label trial.
    Işeri E; Kiliç BG; Senol S; Karabacak NI
    Methods Find Exp Clin Pharmacol; 2007; 29(1):47-52. PubMed ID: 17344944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential disturbance of methylphenidate of gonadal hormones or pubescent development in patients with attention-deficit/hyperactivity disorder: A twelve-month follow-up study.
    Wang LJ; Huang YH; Chou WJ; Lee SY; Tsai CS; Lee MJ; Chou MC
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jun; 108():110181. PubMed ID: 33227299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy.
    Baptista-Neto L; Dodds A; Rao S; Whitney J; Torres A; Gonzalez-Heydrich J
    Expert Opin Investig Drugs; 2008 Jan; 17(1):77-84. PubMed ID: 18095920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guidelines and algorithms for the use of methylphenidate in children with Attention-Deficit/ Hyperactivity Disorder.
    Greenhill L; Beyer DH; Finkleson J; Shaffer D; Biederman J; Conners CK; Gillberg C; Huss M; Jensen P; Kennedy JL; Klein R; Rapoport J; Sagvolden T; Spencer T; Swanson JM; Volkow N
    J Atten Disord; 2002; 6 Suppl 1():S89-100. PubMed ID: 12685523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A post hoc analysis of d-threo-methylphenidate hydrochloride (focalin) versus d,l-threo-methylphenidate hydrochloride (ritalin).
    Weiss M; Wasdell M; Patin J
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1415-21. PubMed ID: 15502601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.
    Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):66-74. PubMed ID: 27183299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations.
    Patrick KS; Radke JL; Raymond JR; Koller L; Nguyen LV; Rodriguez W; Straughn AB
    Pharmacotherapy; 2019 Jun; 39(6):677-688. PubMed ID: 30351459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Newcorn J; Stark JG; McMahen R; Tengler M; Sikes C
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):505-12. PubMed ID: 27228207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ABCB1 c.2677G>T variation is associated with adverse reactions of OROS-methylphenidate in children and adolescents with ADHD.
    Kim SW; Lee JH; Lee SH; Hong HJ; Lee MG; Yook KH
    J Clin Psychopharmacol; 2013 Aug; 33(4):491-8. PubMed ID: 23771192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heart rate variability and methylphenidate in children with ADHD.
    Buchhorn R; Conzelmann A; Willaschek C; Störk D; Taurines R; Renner TJ
    Atten Defic Hyperact Disord; 2012 Jun; 4(2):85-91. PubMed ID: 22328340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder.
    Szobot CM; Rohde LA; Katz B; Ruaro P; Schaefer T; Walcher M; Bukstein O; Pechansky F
    Braz J Med Biol Res; 2008 Mar; 41(3):250-7. PubMed ID: 18327433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed - Results from a randomized, double-blind, placebo-controlled clinical trial.
    Jahangard L; Akbarian S; Haghighi M; Ahmadpanah M; Keshavarzi A; Bajoghli H; Sadeghi Bahmani D; Holsboer-Trachsler E; Brand S
    Psychiatry Res; 2017 May; 251():182-191. PubMed ID: 28213188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B; Karakaya E; Oztop DB
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methylphenidate in Adults with Attention Deficit Hyperactivity Disorder and Substance Use Disorders.
    Simon N; Rolland B; Karila L
    Curr Pharm Des; 2015; 21(23):3359-66. PubMed ID: 26088112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.